A number of Federal and state agencies which share responsibility for the regulation or licensure of medical testing laboratories are concerned about allergy clinics, health centers, and testing laboratories performing the cytotoxic test and promoting the test as effective in the detection of allergic diseases, particularly for food and food additives. The Health Care Financing Administration (HCFA) and the Federal Trade Commission (FTC) have asked FDA to assess the validity, accuracy, and effectiveness of "in vitro" cytotoxic testing as a diagnostic tool. FDA is concerned that businesses may begin distributing kits for cytotoxic testing for which efficacy has not been established.
In a letter dated September 28, 1984, the Joint Council of Allergy and Immunology stated the Council's continued concern regarding the marketing of the cytotoxic test for the diagnosis of allergic diseases and formally requested an updated summary of the agency position on cytotoxic testing.
The cytotoxic test as addressed in this guide refers to any "in vitro" test procedure for the diagnosis of allergy or intolerance to food and ingested substances employing procedures similar to those initially reported by Black in 1956 (1/) and further described by Bryan and Bryan. (2/ - 4/)
The procedure is represented as capable of identifying the presence of specific food allergy or food intolerance based on changes in the appearance, size, shape or integrity of leukocytes that are exposed to extracted food antigens or other materials derived from specific foods.
The test has been identified by a variety of names, including the leukocytotoxicity test, the leukocytic food allergy test, the cytotoxic leukocyte test, or, in advertisements in the lay press simply as the CYTOTOXIC test. Over the past several years, a number of experts and scientific groups have reviewed the cytotoxic test literature and have concluded that the test is unproven. This literature has now also been reviewed by FDA staff and they have reached the same conclusion (see bibliography).
FDA's review of agency records shows that there is no FDA-regulated product on the market that has been demonstrated to be effective in cytotoxic testing nor has any manufacturer submitted evidence to support the marketing of any new product for the cytotoxic test.
FDA has determined that the cytotoxic test remains, in 1985, as an unproven diagnostic procedure unsupported by the scientific literature or well-controlled studies and clinical trials. While there are several reports of uncontrolled studies in the literature which advocate the use of the cytotoxic test, the consensus of scientific opinion is that the cytotoxic test is unreliable as a diagnostic tool and is not generally recognized by qualified experts as effective.
It is the agency position that cytotoxic test kits are devices as that term is defined in section 201(h) of the Federal Food, Drug, and Cosmetic Act. Cytotoxic test kits promoted or offered for the diagnosis of allergic diseases would be adulterated and misbranded unless approval has been granted by FDA. The sections of the Act that would be violated are:
- section 501(f)(1)(B), in that a premarket approval application under section 515 has not been approved and the device is not exempt from premarket approval under the Investigational Device Exemption (IDE) provisions of section 520(g);
- section 502(a), in that the labeling is false *or* misleading;
- section 502(f)(1), in that the device fails to bear adequate directions for lay use of the product and is not exempt under 21 CFR 801.109 (Rx legend); and
- section 502(o), in that the firm has not registered under section 510, or the firm has failed to file a list of each device in commercial distribution as required by section 510(j), and the device was not the subject of a notice or other information as required under section 510(k).
The agency will consider appropriate regulatory action to enforce the statute, if violative test kits are discovered.
*Material between asterisks is new or revised*
- Black, A.P., "A New Diagnostic Method in Allergic Disease," Pediatrics, 17:716-723, 1956.
- Bryan, W.T.K., and M.P. Bryan, "The Application of In Vitro Cytotoxic Reactions to Clinical Diagnosis of Food Allergy," Laryngoscope, 70:810-824, 1960.
- Bryan, W.T.K., and M.P. Bryan, "Cytotoxic Reactions in the Diagnosis of Food Allergy," Laryngoscope, 79:1453-1472, 1969.
- Bryan, W.T.K., and M.P. Bryan, "Clinical Examples of Resolution of Some Idiopathic and Other Diseases by Careful Allergic Management," Laryngoscope, 82:1231-1238, 1972.
- Chambers, V.V., B.H. Hudson, and J Glaser, "A Study of the Reactions of Human Polymorphonuclear Leukocytes to Various Allergens," Journal of Allergy, 29:93-102, 1958.
- Lieberman, P., L. Crawford, J. Bjelland, B. Connell, and M. Rice, "Controlled Study of the Cytotoxic Food Test," Journal of the American Medical Association, 231:728-730, 1975.
- Benson, T.E., and J.A. Arkins, "Cytotoxic Testing for Food Allergy: Evaluation of Reproducibility and Correlation," Journal of Allergy and Clinical Immunology, 58:471-476, 1976.
- Lehman, C.W., "The Leukocytic Food Allergy Test: A Study of its Reliability and Reproducibility. Effect of Diet and Sublingual Food Drops on this test," Annals of Allergy, 45:150-158, 1980.
- Report From the NCHCT, "Summary of Assessments, 1981," Journal of the American Medical Association, 246:1499, 1981.
- American Academy of Allergy, "Position Statements--Controversial Techniques," Journal of Allergy and Clinical Immunology, 67:333-334, 1981.
- Greico, M.H. "Controversial Practices in Allergy," Journal of the American Medical Association, 247:3106-3111, 1982.
- Golbert, T.M., "A Review of Controversial Diagnostic and Therapeutic techniques employed in Allergy," Journal of Allergy and Clinical Immunology, 56:170-190, 1975.
- Updegraff, T.R., "Food Allergy and Cytotoxic Tests," Ear, Nose & Throat Journal, 56:7-16, 1977
- Boyles, J.H., Jr., "The Validity of Using the Cytotoxic Food Test in Clinical Allergy," Ear, Nose & Throat, Reprint: 1-6, 1977.
- Ulett, G.A., and S.G., Perry, "Cytotoxic Testing and Leucocyte Increase as an Index to Food Sensitivity," Annals of Allergy, 33:17-26, 1974.
- Ruokonen, J., E. Holopanianen, T. Palva, "Secretary Otitis Media and Allergy," Allergy, 36:59-68.
- Holopainen, E., T. Palva, P. Stenberg, A. Buckman, H. Lehti, and J. Ruokonen, "Cytotoxic Leucocyte Reaction," Acta Otolaryngol, 89:222-226, 1980.
- Ulett, G.A., and S.G. Perry, "Cytotoxic Testing and Leucocyte Increase as an Index to Food Sensitivity II. Coffee and Tobacco," Annals of Allergy, 34:150-160, 1975.
Revised: 9/24/87, 3/95
Submit comments on this guidance document electronically via docket ID: FDA-2013-S-0610 - Specific Electronic Submissions Intended For FDA's Dockets Management Staff (i.e., Citizen Petitions, Draft Proposed Guidance Documents, Variances, and other administrative record submissions)
If unable to submit comments online, please mail written comments to:
Food and Drug Administration
5630 Fishers Lane, Rm 1061
Rockville, MD 20852
All comments should be identified with the title of the guidance.